![](/wp-content/uploads/2021/12/Dec-14.21-Blast-Cover.png)
$599
Sigilon Announces Strategic Reprioritization; Jaguar Gene Therapy Includes T1DM in Initial Pipeline Program
Two cardiometabolic-related news items have been observed: Sigilon Therapeutics announced plans for a strategic reprioritization to focus on its MPS-1 and beta cell therapy for T1DM, including a 38% workforce reduction; and Jaguar Gene Therapy announced target genes for its initial pipeline programs in T1DM, autism, and T1 Galactosemia. Below, FENIX provides highlights and insights for the respective new items.